InsidersTradesSigma
Follow the Humacyte, Inc. stock price and the full management transaction log of the company, a listed issuer based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Humacyte, Inc. has logged 95 insider filings. The latest transaction was disclosed on 21 August 2026 (Acquisition). Among the most active insiders: Dougan Brady W. Every trade is accessible without an account.
95
Insider Decl.
n/a
Thresholds
€1m
34 ops.
Buy Volume
€127m
38 ops.
Sell Volume
43Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 21 August 2026
Declarations95 total
10,000 shares@ US$0.693Common StockSEC:0001193125-26-361081:0
Canonical exit: 18 Nov 2026 (T+90)
30,000 shares@ US$0.594100.0% of flowCommon StockSEC:0001193125-26-356847:0
Canonical exit: 15 Nov 2026 (T+90)
311,100 shares0Common StockSEC:0001628280-25-052723:0
311,100 shares0Common StockSEC:0001628280-25-052720:0
549,360 shares@ US$1.831.8% of flowCommon StockSEC:0001104659-25-081009:0
549,360 shares@ US$1.831.8% of flowCommon StockSEC:0001104659-25-081008:0
6,493 shares@ US$1.5412.6% of flowCommon StockSEC:0001818382-25-000052:0
Canonical exit: 13 Jul 2025 (T+90)
20,000 shares@ US$1.5321.6% of flowCommon StockSEC:0001818382-25-000050:0
Canonical exit: 9 Jul 2025 (T+90)
7,500 shares@ US$1.55100.0% of flowCommon StockSEC:0001818382-25-000049:0
Canonical exit: 9 Jul 2025 (T+90)
6,000 shares@ US$1.2944.1% of flowCommon StockSEC:0001818382-25-000045:0
Canonical exit: 7 Jul 2025 (T+90)
50,000 shares@ US$1.3235.0% of flowCommon StockSEC:0001818382-25-000046:0
Canonical exit: 7 Jul 2025 (T+90)
16,000 shares@ US$1.2621.3% of flowCommon StockSEC:0001818382-25-000044:0
Canonical exit: 6 Jul 2025 (T+90)
4,600 shares@ US$4.387222.1% of flowCommon StockSEC:0001818382-24-000216:0
Canonical exit: 4 Mar 2025 (T+90)
1,797 shares@ US$4.440.0% of flowCommon StockSEC:0001818382-24-000213:0
Canonical exit: 17 Feb 2025 (T+90)
1,797 shares@ US$4.440.0% of flowCommon StockSEC:0001818382-24-000214:0
Canonical exit: 17 Feb 2025 (T+90)
811,172 shares@ US$4.447.1% of flowCommon StockSEC:0001818382-24-000208:0
811,172 shares@ US$4.447.1% of flowCommon StockSEC:0001818382-24-000206:0
1,200 shares@ US$4.0927.7% of flowCommon StockSEC:0001818382-24-000189:0
4,521 shares@ US$4.3410.4% of flowCommon StockSEC:0001818382-24-000186:0
157,704 shares@ US$5.421.6% of flowCommon StockSEC:0001818382-24-000185:0
157,704 shares@ US$5.421.6% of flowCommon StockSEC:0001818382-24-000184:0
1,222 shares@ US$6.5450.0% of flowCommon StockSEC:0001818382-24-000175:0
Canonical exit: 27 Nov 2024 (T+90)
1,222 shares@ US$6.5450.0% of flowCommon StockSEC:0001818382-24-000177:0
Canonical exit: 27 Nov 2024 (T+90)
252,676 shares@ US$6.713.2% of flowCommon StockSEC:0001818382-24-000166:0
252,676 shares@ US$6.713.2% of flowCommon StockSEC:0001818382-24-000167:0
25 of 95 declarations
关于 Humacyte, Inc.
Humacyte, Inc. 是一家总部位于美国的生物技术公司，在美国纳斯达克上市，它最好被理解为一个再生医学平台，而非单一产品公司。该公司总部位于北卡罗来纳州达勒姆，由 Laura Niklason 于 2004 年创立，她是一位医生兼科学家，因其在组织工程领域的工作而广受认可。其核心使命是开发可普遍植入的生物工程人体组织，这些组织可以即时使用，无需从患者身上获取组织。Humacyte 的技术围绕无细胞结构构建，旨在植入后成为活体组织。([investors.humacyte.com](https://investors.humacyte.com/news-releases/news-release-details/humacyte-appoints-founder-laura-niklason-md-phd-president-and/?utm_source=openai)) 该公司的主要商业重点是其 ATEV（无细胞组织工程血管）系列产品。旗舰产品 Symvess® 定位用于肢体血管创伤修复，是近期主要的商业驱动力。除了创伤，Humacyte 还在推进其他血管机会，包括用于血液透析的动静脉通路和外周动脉疾病，同时维持冠状动脉搭桥移植、儿科心脏手术、1 型糖尿病和其他组织工程应用的临床前项目。在投资者材料中，管理层将该平台描述为广泛适用于多种解剖结构和疾病类别。([investors.humacyte.com](https://investors.humacyte.com/?utm_source=openai)) 从竞争角度来看，Humacyte 的差异化在于试图解决血管外科手术中几个长期存在的局限性：移植物可用性、感染风险以及传统导管的性能限制。该公司认为，其即时可用、普遍植入的方法可以改善临床工作流程和患者预后，尤其是在紧急情况下。尽管如此，这仍然是一家市值较小的生物技术公司，具有显著的执行风险。商业推广、报销、生产规模扩大和监管进展对投资案例都至关重要，公司仍依赖资本市场为开发和上市活动提供资金。([investors.humacyte.com](https://investors.humacyte.com/news-releases/news-release-details/humacyte-announces-presentation-symvessr-long-term-safety-and?utm_source=openai)) Humacyte 的运营基地位于北卡罗来纳州达勒姆，其总部、制造能力和研发职能均设在美国。该公司还通过战略合作伙伴关系拥有国际商业化足迹，包括与 Fresenius Medical Care 合作，获得某些非美国血管权利。2026 年的最新进展包括 Symvess 的商业发布、长期临床数据演示、医疗经济学分析、以色列营销授权申请的接受，以及为支持商业化和即将到来的临床里程碑而进行的注册直接融资。这些事件凸显了公司正从开发阶段的生物技术公司向早期商业化转型，同时仍面临高度的监管和商业敏感性。([investors.humacyte.com](https://investors.humacyte.com/news-releases/news-release-details/humacyte-announces-commercial-launch-symvesstm-acellular-tissue/?utm_source=openai))
